Interferon α plus adefovir dipivoxil therapy for patients with HBeAg positive chronic hepatitis B nonresponding to interferon monotherapy
10.3760/cma.j.issn.1674-2397.2013.02.007
- VernacularTitle:干扰素α联合阿德福韦酯对干扰素治疗无应答HBeAg阳性慢性乙型肝炎疗效观察
- Author:
Hongjie OU
;
Xiaolu WU
;
Jiajun LIU
- Publication Type:Journal Article
- Keywords:
Chronic hepatitis B;
Interferon alpha;
Adefovir dipivoxil;
Combination therapy
- From:
Chinese Journal of Clinical Infectious Diseases
2013;(2):86-89
- CountryChina
- Language:Chinese
-
Abstract:
Objective To evaluate the efficacy and safety of interferon alpha (IFNα) combined with adefovir dipivoxil (ADV) for patients with chronic hepatitis B (CHB) non-responding to 24-week IFNα monotherapy.Methods Sixty CHB patients admitted to the First Affiliated Hospital of Xiamen University during 2009 and 2012 were enrolled in the study.All patients recieved IFNα monotherapy for 24 weeks and had no response.The patients were randomly divided into 3 groups by number table with 20 cases in each group.The experimental group was treated with IFNα combined with ADV,the control group 1 continued IFNα monotherapy,and the control group 2 shifted to ADV monotherapy.Virological,serological and biochemical responses were compared,and adverse reactions were observed.SPSS 19.0 software was used for data analysis.Results After 24 weeks of treatment,there was no statistical difference in HBV DNA loads,ALT levels and titers of HBeAg and HBsAg among three groups (F =0.985,0.717,0.985 and 0.717,P ＞ 0.05).And no HBeAg seroconversion was observed.After 48 weeks of treatment,the experimental group had higher HBV DNA negative conversion rate,ALT normalization rate and HBeAg conversion rate than control group 1 (x2 =10.00,3.956 and 4.800,P ＜ 0.05),but no statistically significant difference was found in HBeAg negative conversion rate (x2 =0.693,P ＞ 0.05).There was no significant difference in HBV DNA and HBeAg negative conversion rates between experimental group and the control group 2 (x2 =1.026,1.905 and 0.156,P ＞0.05),but the HBeAg conversion rate in experimental group was significantly higher than that in control group 2 (x2 =4.800,P ＜ 0.05).No HBsAg negative or serological conversion was observed,and there was no significant difference in titers of HBsAg among three groups (F =1.935,P ＞ 0.05).No adverse reaction was observed.Conclusion For patients nonresponding to IFNα monotherapy,combination of IFNα and ADV can achieve higher ALT normalization rate,HBeAg conversion rate and HBV DNA negative conversion rate,and improve the overall efficacy of CHB antiviral therapy.
